All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The Lupus Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lymphoma Hub

Lymphoma Hub

MDS Hub

MDS Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2023-03-27T09:09:39.000Z

What do HCPs need to know about LN and the prevention of progression to ESRD?

By Mark Maitland, Sam Larkin, Jennifer Higgins
Featured
Murray Urowitz
Mar 27, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new development in lupus nephritis.

Bookmark this article

The Lupus Hub was pleased to speak to Murray Urowitz, University of Toronto, Toronto, CA. We asked, What do HCPs need to know about LN and the prevention of progression to end-stage renal disease (ESRD)?

What do HCPs need to know about LN and the prevention of progression to ESRD?

Urowitz begins by highlighting the incidence of ESRD in patients with lupus, with estimates ranging from 8% to 17% over 10 years. He then examines the factors associated with advancement to Grade 4 and 5 chronic kidney disease. He also presents data on the relationship between time to remission, number of flares in the first 5 years after initial remission, and the number of years a patient is on immunosuppressant therapy with the development of chronic kidney disease. Finally, he discusses how this data could inform lupus treatment and ultimately reduce the incidence of progression to ESRD.

More about...
Lupus nephritisSystemic lupus erythematosus

Related articles

Add bookmark

Using the EULAR/ACR criteria to assess organ damage in patients with SLE and LN

Here, we evaluate EULAR/ACR criteria as a prognostic tool for patients with SLE and explore the relationship between lupus nephritis at diagnosis and organ damage after 3...

Mar 31, 2023
Add bookmark

Using the EULAR/ACR criteria to assess organ damage in patients with SLE and LN

Here, we evaluate EULAR/ACR criteria as a prognostic tool for patients with SLE and explore the relationship between...

Mar 31, 2023
Add bookmark

Editorial theme | Trajectories of depressive symptoms in SLE

Here, we discuss the impact of depression on quality of life in patients with SLE and the risk factors associated with depression from a paper by Chawla et al.

Feb 24, 2023
Add bookmark

Editorial theme | Trajectories of depressive symptoms in SLE

Here, we discuss the impact of depression on quality of life in patients with SLE and the risk factors associated with depression from a...

Feb 24, 2023

Newsletter

Subscribe to get the best content related to lupus delivered to your inbox